This is revealed by a new analysis to be presented by Novo Nordisk today at the
'Invitation to growth - a road to job creation' conference. The analysis homes in on the value created in the interaction between growth businesses and public-sector research and education, as well as the challenges that must be solved so that research-based businesses can continue to grow in Denmark.
"With the expectation of creating 6,000 new jobs in Denmark over the coming years, it will be crucial for Novo Nordisk that Denmark educates world-class graduates but also focuses far more intently on attracting international talent," says Executive Vice President and Chief Science Officer Mads Krogsgaard Thomsen.
The analysis presents new forecasts for the future availability of university graduates and PhDs and questions whether Denmark is investing sufficiently in the frameworks that are necessary for providing strong research-based degree programmes.
The conference is being hosted today by Novo Nordisk from 12.30 to 16.30 at the company's headquarters in Bagsværd. The debaters will include Danish Minister for Higher Education and Science Sofie Carsten Nielsen; Chair of the Government's Expert Committee on Quality in Higher Education Jørgen Søndergaard; Rector of the University of Copenhagen Ralf Hemmingsen; and the political spokespersons for the Liberal Party of Denmark and the Danish Social Democrats.
The analysis is available at novonordisk.com; photosand b-rollfrom Novo Nordisk's Research & Development department are also available for download from novonordisk.com.
Corporate Communications
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
Page 2 of 2
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk employs approximately
40,000 employees in 75 countries, and markets its products in more than 180 countries. For more
information, visit novonordisk.com.
Further informationMedia:
Mette Kruse Danielsen +45 3079 3883 mkd@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
Investors:
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Jannick Lindegaard Denholt | +45 3079 8519 | jlis@novonordisk.com |
Lars Borup Jacobsen | +45 3075 3479 | lbpj@novonordisk.com |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com |
Corporate Communications
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet: www.novonordisk.com CVR no:
24 25 67 90
distributed by |